Gabelli Funds’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Gabelli Funds’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-863,020	Closed	-$1.94M	–	1261
2020 Q3	$1.94M	Sell	863,020 -993	-0.1%	-$2.84K	0.02%	685
2020 Q2	$3.09M	Sell	864,013 -158,466	-15%	-$572K	0.03%	559
2020 Q1	$3.88M	Buy	1,022,479 +79,152	+8%	+$261K	0.03%	469
2019 Q4	$2.84M	Buy	+943,327	New	+$2.45M	0.02%	649

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Gabelli Funds's BMY.RT Position: Q4 2020 in Review

Gabelli Funds sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 863,020 shares — an estimated $1.94M sold.

Gabelli Funds first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $3.88M in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Gabelli Funds reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Gabelli Funds sold 863,020 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $1.94M.
Gabelli Funds first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Gabelli Funds's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.88M in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Gabelli Funds's 13F filing for Q4 2020, filed 5 Feb 2021.